N/A
Completed N=1,704
Radiologic Evaluation and Breast Density (READ)
Source: ClinicalTrials.gov NCT00117663 ↗Enrolled (actual)
1,704
Serious AEs
0.6%
Results posted
Apr 2024
Primary outcomePrimary: Mammogram Recall for Additional Imaging — 11.3; 12.3; 9.8 percentage of women recalled
Summary
The purpose of this study is to determine whether cessation of hormone replacement therapy for one or two months before a screening mammogram will improve its performance by decreasing breast density.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mammogram Recall for Additional Imaging |
11.3; 12.3; 9.8 | — |
| PRIMARY Mammographic Breast Density |
0.1; -0.9; -1.5 | — |
Eligibility Criteria
Inclusion Criteria
- 1 or more prior screening mammograms at Group Health Cooperative within the past 2 years
- Currently taking HRT
- Taking HRT at prior screening mammogram
- Due for a screening mammogram
Exclusion Criteria
- BI-RADS breast density of 1 (entirely fat)
- Previous cardiovascular events (heart surgery, catheterization, stent bypass, angioplasty, stroke, DVT)
- Previous breast cancer
- History of breast implants
- Breast reduction since last mammogram
- Mastectomy
- History of using Tamoxifen or Raloxifene
- Declined contact or use of data for research
Data sourced from ClinicalTrials.gov (NCT00117663). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.